TISSUE REPAIR LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.22 AUD | -4.35% |
|
0.00% | 0.00% |
| Feb. 29 | Tissue Repair Limited Announces Change of Company Secretary | CI |
| Feb. 28 | Tissue Repair Ltd Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| Sales 2022 | 172K 114K | Sales 2023 | 972K 646K | Capitalization | 16.33M 10.85M |
|---|---|---|---|---|---|
| Net income 2022 | -6M -3.99M | Net income 2023 | -4M -2.66M | EV / Sales 2022 | -60.1 x |
| Net cash position 2022 | 25.46M 16.93M | Net cash position 2023 | 21.4M 14.23M | EV / Sales 2023 | -5.22 x |
| P/E ratio 2022 |
-1.82
x | P/E ratio 2023 |
-3.91
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 42.38% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.35% | ||
| Current month | -4.35% | ||
| 1 month | -10.20% | ||
| 3 months | -2.22% | ||
| 6 months | -6.38% |
1 week
0.22
0.24
1 month
0.220.25
Current year
0.220.26
1 year
0.210.34
3 years
0.200.83
5 years
0.200.83
10 years
0.200.83
| Managers | Title | Age | Since |
|---|---|---|---|
Cameron Jones
DFI | Director of Finance/CFO | - | - |
Mark Waring
CTO | Chief Tech/Sci/R&D Officer | - | - |
Darryl Reed
COO | Chief Operating Officer | - | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 21-08-12 | |
Tony Charara
FOU | Founder | - | 11-12-31 |
| Director/Board Member | - | 21-10-06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-03 | 0.22 | -4.35% | 15 000 |
| 24-05-31 | 0.23 | -2.13% | 9 |
| 24-05-29 | 0.235 | +6.82% | 13,935 |
Delayed Quote Australian S.E., June 03, 2024 at 09:41 pm EDT
More quotes
Tissue Repair Limited is an Australia-based Phase 3 advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987, with a secondary focus on commercializing TR Pro+ a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures. Its TR Pro+ product provides a range of benefits that assists damaged skin to heal and maintains skin hydration for a moist healing environment to encourage normal scar formation. The Company is also focused on commercializing its propriety Glucoprime active pharmaceutical ingredient (API) to treat a variety of wounds and skin conditions. Glucoprime is a β-glucan molecule, which is designed to assist skin healing and is delivered topically in a hydrogel formulation.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 9.29M | |
| +15.74% | 121B | |
| +13.50% | 107B | |
| -5.38% | 24.82B | |
| +1.69% | 22.48B | |
| -10.09% | 18.32B | |
| -40.52% | 16.33B | |
| -14.57% | 15.31B | |
| +3.32% | 14.08B | |
| +24.88% | 11.74B |
- Stock Market
- Equities
- TRP Stock
